Kayla N Kleist - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Frontiers in Neurology|January 26, 2026

ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzoleAndrée-Anne Berthiaume, Kayla N Kleist, Sherif M Reda, et al.

Frontiers in Neuroscience|February 23, 2024

ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALSAndrée-Anne Berthiaume, Sherif M Reda, Kayla N Kleist, et al.

Nature Communications|April 5, 2022

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunityMark F Maurer, Katherine E Lewis, Joseph L Kuijper, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Frontiers in Neurology|January 26, 2026

ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzoleAndrée-Anne Berthiaume, Kayla N Kleist, Sherif M Reda, et al.

Frontiers in Neuroscience|February 23, 2024

ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALSAndrée-Anne Berthiaume, Sherif M Reda, Kayla N Kleist, et al.

Nature Communications|April 5, 2022

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunityMark F Maurer, Katherine E Lewis, Joseph L Kuijper, et al.

Pageof 1